- Home
- IVR vs MYGN Comparison
IVR vs MYGN Comparison
Compare IVR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVR
- MYGN
- Stock Information
- Founded
- IVR 2008
- MYGN 1991
- Country
- IVR United States
- MYGN United States
- Employees
- IVR N/A
- MYGN N/A
- Industry
- IVR Real Estate Investment Trusts
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IVR Real Estate
- MYGN Health Care
- Exchange
- IVR Nasdaq
- MYGN Nasdaq
- Market Cap
- IVR 493.9M
- MYGN 423.1M
- IPO Year
- IVR 2009
- MYGN 1995
- Fundamental
- Price
- IVR $7.61
- MYGN $6.32
- Analyst Decision
- IVR Hold
- MYGN Hold
- Analyst Count
- IVR 3
- MYGN 15
- Target Price
- IVR $7.25
- MYGN $15.14
- AVG Volume (30 Days)
- IVR 1.7M
- MYGN 2.4M
- Earning Date
- IVR 07-24-2025
- MYGN 08-05-2025
- Dividend Yield
- IVR 17.87%
- MYGN N/A
- EPS Growth
- IVR N/A
- MYGN N/A
- EPS
- IVR 0.32
- MYGN N/A
- Revenue
- IVR $59,701,000.00
- MYGN $832,900,000.00
- Revenue This Year
- IVR $278.42
- MYGN N/A
- Revenue Next Year
- IVR N/A
- MYGN $6.64
- P/E Ratio
- IVR $23.86
- MYGN N/A
- Revenue Growth
- IVR 1793.56
- MYGN 3.83
- 52 Week Low
- IVR $5.86
- MYGN $3.76
- 52 Week High
- IVR $9.42
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- IVR 49.55
- MYGN 70.39
- Support Level
- IVR $7.54
- MYGN $3.76
- Resistance Level
- IVR $7.80
- MYGN $4.09
- Average True Range (ATR)
- IVR 0.16
- MYGN 0.30
- MACD
- IVR 0.01
- MYGN 0.23
- Stochastic Oscillator
- IVR 66.38
- MYGN 96.97
About IVR INVESCO MORTGAGE CAPITAL INC
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.